The stock may react negatively to the down guidance despite strong 2025 results. Traders should monitor the progress of the Hydronidone NDA in China and the Cullgen acquisition closing for potential upside. The decline in GAAP net income amid rising operating expenses warrants caution on profitability trends.
Price Chart
Executive Summary
Gyre Therapeutics reported solid full-year 2025 revenue growth of 10.2% to $116.6 million, driven by new product launches and strong commercial execution. However, the company issued 2026 revenue guidance of $100.5M–$111.0M, signaling a projected decline of 4.8%–13.8%, citing a strategic shift toward regulatory priorities and reduced promotion for newer products. The filing also announced a $300M all-stock acquisition of Cullgen and key pipeline advances, including an expected NDA submission for Hydronidone in China in 2026.
Key Financial Metrics
Key Facts
- Full-year 2025 revenue: $116.6M, up 10.2% YoY
- 2026 revenue guidance: $100.5M–$111.0M, representing a 4.8%–13.8% decline from 2025
- Q4 2025 revenue: $37.2M, up 33.3% YoY
- Net income declined from $17.9M in 2024 to $9.9M in 2025
- Non-GAAP adjusted net income increased from $16.9M to $18.9M in 2025
- Announced $300M all-stock acquisition of Cullgen, expected to close Q2 2026
- Plans NDA submission for Hydronidone in China in 1H 2026, with potential for conditional approval
- Completed enrollment in Phase 3 pirfenidone trial for pneumoconiosis; results expected in Q3 2026
- Cash position: $75.9M as of December 31, 2025
Financial Impact
Revenue expected to decline by $5.6M–$16.1M in 2026 vs. 2025; acquisition of Cullgen valued at $300M in stock adds pipeline but increases dilution risk
Risk Factors
- 2026 revenue guidance implies contraction, potentially signaling commercial or regulatory headwinds
- All-stock acquisition of Cullgen may dilute existing shareholders
- Reliance on conditional approval pathway for Hydronidone in China introduces regulatory uncertainty
- Increased selling and marketing spend ($65.2M in 2025) not translating into accelerating revenue growth
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3254390 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $5.85 | awaiting T+20 | — | $6.53 (+11.62%) |
Sep 1, 2026 8w ago | 8-K | $6.47 $7.35 | ▲ +13.52% | ▲ +12.34% | $6.53 (+0.93%) |
Aug 26, 2026 8w ago | 8-K | $6.65 $7.43 | ▲ +11.73% | ▲ +10.53% | $6.53 (−1.80%) |
Aug 7, 2026 11w ago | 8-K | $6.67 $6.86 | ▼ −2.85% | ▼ −3.25% | $6.53 (+2.10%) |
Aug 4, 2026 12w ago | EFFECT | $6.15 $6.47 | ▲ +5.20% | ▲ +6.44% | $6.53 (+6.18%) |
Jul 13, 2026 15w ago | S-3/A | $6.34 $6.64 | ▲ +4.73% | ▲ +2.24% | $6.53 (+3.00%) |
Jun 2, 2026 21w ago | 8-K | $5.56 $6.52 | ▲ +17.27% | ▲ +18.83% | $6.53 (+17.45%) |
May 14, 2026 23w ago | 8-K | $6.55 $5.86 | ▼ −10.53% | ▼ −12.65% | $6.53 (−0.31%) |
May 4, 2026 25w ago | 8-K / DEFA14A | $7.92 $5.81 | ▼ −26.64% | ▼ −32.29% | $6.53 (−17.55%) |
May 4, 2026 25w ago | Press Release | $7.92 $5.81 | ▼ −26.64% | ▼ −32.29% | $6.53 (−17.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers